cyclocreatine has been researched along with Disease Models, Animal in 9 studies
cyclocreatine: structure given in first source
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Creatine Transporter Deficiency (CTD) is an inborn error of metabolism presenting with intellectual disability, behavioral disturbances and epilepsy." | 3.96 | Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency. ( Alessandrì, MG; Baroncelli, L; Battini, R; Butt, M; Cacciante, F; Cerri, E; Cioni, G; Do, MT; Gennaro, M; Lupori, L; Mazziotti, R; McKew, JC; Pizzorusso, T; Putignano, E; Sagona, G, 2020) |
| "Creatine treatment was associated with enhanced cellular basal respiration in vitro and increased tumor cell proliferation in vivo." | 1.72 | Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression. ( Fleming, J; Ford, CA; Leung, HY; Lynch, V; Mackay, G; Mui, E; Patel, R; Rodgers, L; Rushworth, LK; Sansom, OJ; Sumpton, D; Vande Voorde, J; Watson, D; Zhang, T, 2022) |
| " Exposure at the no observed adverse effect level in creatine transporter-deficient (554 μg*hr/ml) mice exceeded exposure at the maximum tolerated dose in wild-type (248 μg*hr/ml) mice." | 1.62 | Use of an animal model of disease for toxicology enables identification of a juvenile no observed adverse effect level for cyclocreatine in creatine transporter deficiency. ( Butt, M; Cavagnaro, J; Do, MT; McKew, JC; Terse, PS, 2021) |
| "Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic variants of TREM2, a surface receptor required for microglial responses to neurodegeneration, including proliferation, survival, clustering, and phagocytosis." | 1.46 | TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease. ( Artyomov, MN; Beatty, WL; Cairns, NJ; Cella, M; Colonna, M; Gilfillan, S; Holtzman, DM; Huang, SC; Kambal, A; Loboda, AA; Loginicheva, E; Sergushichev, A; Song, WM; Ulland, TK; Ulrich, JD; Unanue, ER; Virgin, HW; Wang, Y; Zhou, Y, 2017) |
| "Cyclocreatine-treated Slc6a8-/y mice also exhibited a profound improvement in cognitive abilities, as seen with novel object recognition as well as spatial learning and memory tests." | 1.38 | Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency. ( Benoit, SC; Blanco, VM; Chambers, JB; Clark, JF; Daikoku, T; Degrauw, TJ; Kurosawa, Y; Lindquist, DM; Pyne-Geithman, GJ, 2012) |
| "The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism." | 1.30 | Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998) |
| "Cyclocreatine was not very cytotoxic upon 24 h of exposure of human SW2 small-cell lung cancer cells to concentrations of up to 5 mM." | 1.29 | Cyclocreatine in cancer chemotherapy. ( Kaddurah-Daouk, R; Kufe, DW; Liu, J; Menon, K; Northey, D; Teicher, BA, 1995) |
| "Cyclocreatine-treated dogs (n = 6) were injected intravenously with cyclocreatine solution (600 mg/kg) 1 h before the experiment and during ligation of the coronary artery." | 1.29 | Cyclocreatine inhibits neutrophil accumulation in the myocardium of a canine model of coronary artery occlusion and reperfusion. ( Allam, ME; Elgebaly, SA; Forouhar, F; Hashmi, F; Houser, S; Miano, D, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, R | 1 |
| Ford, CA | 1 |
| Rodgers, L | 1 |
| Rushworth, LK | 1 |
| Fleming, J | 1 |
| Mui, E | 1 |
| Zhang, T | 1 |
| Watson, D | 1 |
| Lynch, V | 1 |
| Mackay, G | 1 |
| Sumpton, D | 1 |
| Sansom, OJ | 1 |
| Vande Voorde, J | 1 |
| Leung, HY | 1 |
| Cacciante, F | 1 |
| Gennaro, M | 1 |
| Sagona, G | 1 |
| Mazziotti, R | 1 |
| Lupori, L | 1 |
| Cerri, E | 1 |
| Putignano, E | 1 |
| Butt, M | 2 |
| Do, MT | 2 |
| McKew, JC | 2 |
| Alessandrì, MG | 1 |
| Battini, R | 1 |
| Cioni, G | 1 |
| Pizzorusso, T | 1 |
| Baroncelli, L | 1 |
| Cavagnaro, J | 1 |
| Terse, PS | 1 |
| Ulland, TK | 1 |
| Song, WM | 1 |
| Huang, SC | 1 |
| Ulrich, JD | 1 |
| Sergushichev, A | 1 |
| Beatty, WL | 1 |
| Loboda, AA | 1 |
| Zhou, Y | 1 |
| Cairns, NJ | 1 |
| Kambal, A | 1 |
| Loginicheva, E | 1 |
| Gilfillan, S | 1 |
| Cella, M | 1 |
| Virgin, HW | 1 |
| Unanue, ER | 1 |
| Wang, Y | 1 |
| Artyomov, MN | 1 |
| Holtzman, DM | 1 |
| Colonna, M | 1 |
| Kurosawa, Y | 1 |
| Degrauw, TJ | 1 |
| Lindquist, DM | 1 |
| Blanco, VM | 1 |
| Pyne-Geithman, GJ | 1 |
| Daikoku, T | 1 |
| Chambers, JB | 1 |
| Benoit, SC | 1 |
| Clark, JF | 1 |
| Teicher, BA | 1 |
| Menon, K | 1 |
| Northey, D | 1 |
| Liu, J | 1 |
| Kufe, DW | 1 |
| Kaddurah-Daouk, R | 3 |
| Lillie, JW | 1 |
| Smee, DF | 1 |
| Huffman, JH | 1 |
| Hansen, LJ | 1 |
| Sidwell, RW | 1 |
| Elgebaly, SA | 1 |
| Allam, ME | 1 |
| Houser, S | 1 |
| Hashmi, F | 1 |
| Forouhar, F | 1 |
| Miano, D | 1 |
| Matthews, RT | 1 |
| Yang, L | 1 |
| Jenkins, BG | 1 |
| Ferrante, RJ | 1 |
| Rosen, BR | 1 |
| Beal, MF | 1 |
9 other studies available for cyclocreatine and Disease Models, Animal
| Article | Year |
|---|---|
Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.
Topics: Animals; Creatine; Creatinine; Disease Models, Animal; Humans; Intracellular Signaling Peptides and | 2022 |
Cyclocreatine treatment ameliorates the cognitive, autistic and epileptic phenotype in a mouse model of Creatine Transporter Deficiency.
Topics: Animals; Autistic Disorder; Blood-Brain Barrier; Brain Diseases, Metabolic, Inborn; Cerebrovascular | 2020 |
Use of an animal model of disease for toxicology enables identification of a juvenile no observed adverse effect level for cyclocreatine in creatine transporter deficiency.
Topics: Animals; Antineoplastic Agents; Brain; Brain Diseases, Metabolic, Inborn; Creatine; Creatinine; Dise | 2021 |
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.
Topics: Alzheimer Disease; AMP-Activated Protein Kinases; Animals; Autophagy; Creatinine; Disease Models, An | 2017 |
Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency.
Topics: Animals; Base Sequence; Brain; Cognition; Cognition Disorders; Creatinine; Disease Models, Animal; D | 2012 |
Cyclocreatine in cancer chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Small Cell; Carmustine; Cell Division; Ce | 1995 |
Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits the replication of human herpes viruses.
Topics: Acyclovir; Animals; Creatinine; Disease Models, Animal; Drug Resistance, Microbial; Drug Therapy, Co | 1994 |
Cyclocreatine inhibits neutrophil accumulation in the myocardium of a canine model of coronary artery occlusion and reperfusion.
Topics: Amino Acid Sequence; Animals; Chemotactic Factors; Chemotaxis, Leukocyte; Coronary Disease; Creatini | 1993 |
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin | 1998 |